Use your browser's back button to choose another title or click here for a New Search.

How to Get the Poster

 Open slide (ppt)


Bookmark and Share

Hepatitis B Virus and Hepatitis C Virus Services Offered by Substance Abuse Treatment Programs in the United States.

Poster presented at the College on Problems of Drug Dependence (CPDD) annual meeting, Quebec City, Canada, June 16-21, 2007.

Edmund J. Bini, MD, MPH (VA New York Harbor Healthcare System, NY Node), Steven Allan Kritz, MD (Addiction Research and Treatment Corporation, NY Node), Lawrence S. Brown Jr., MD, MPH (Addiction Research and Treatment Corporation, NY Node), James A. Robinson, MEd (Nathan Kline Institute for Psychiatric Research, NY/LI Node), Donald Alderson, MS (New York State Psychiatric Institute, NY Node), Patrick McAuliffe, MBA, LADC (Connecticut Renaissance, Inc., NE Node), Cheryl Smith, MD (NY State Department of Health, NY Node), John Rotrosen, MD (New York University, NY Node), CTN Infections Study Team (CTN-0012).

Although substance abuse treatment programs are an important point of contact to provide health services to diagnose, treat and prevent transmission of hepatitis B (HBV) and hepatitis C (HCV) viral infection, little is known about the availability of these services in substance abuse programs. This presentation reports on a study that evaluated the prevalence and spectrum of HBV and HCV services offered by drug treatment programs in the U.S. A questionnaire-based survey of drug treatment programs within the National Drug Abuse Treatment Clinical Trials Network was conducted as part of protocol CTN-0012 ("Characteristics of Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infections, and Sexually Transmitted Infections in Substance Abuse Treatment Programs"). Completed questionnaires were received from 269 (84.3%) of the 319 program administrators. Although 78.7% of programs reported that they offered ongoing hepatitis training for clinical staff, only a minority of programs offered testing for HBsAg (37.7%), HBsAb (36.7%), HBcAb (27.7%), HBV DNA (7.8%), HCV antibodies (52.9%), HCV qualitative (10.1%) or quantitative (8.9%) PCR, and HCV genotyping (11.6%). Hepatitis A and B vaccinations were offered by 68.3% of programs, either on site (19.3%) or via referral (49.1%). Programs having clear guidelines for hepatitis testing were significantly more likely to offer each of the hepatitis tests as compared with those that did not have clear guidelines. Only 28.9% of programs offered HCV treatment either on-site or via referral. Despite the importance of substance abuse in sustaining the hepatitis epidemics in the U.S., many substance abuse treatment programs do not offer comprehensive HBV, HCV and hepatitis vaccination services. Public health interventions to improve access to hepatitis testing, treatment and prevention for substance abusers are needed.(Poster, PowerPoint slides, English, 2007)

Keywords: Community health services | Health services research | Hepatitis B | Hepatitis C | HIV/AIDS | Sexually transmitted diseases | College on Problems of Drug Dependence (CPDD) annual meeting, 2007

Document No: 219

Submitted by Steven Kritz, M.D., New York Node (6/26/2007).

Alderson, Donald search
Bini, Edmund J. search mail
Brown, Lawrence S. Jr. search mail
Kritz, Steven Allan search mail
McAuliffe, Patrick search
Robinson, James A. search mail
Rotrosen, John search mail
Smith, Cheryl search
NIDA-CTN-0012 search www
All Nodes and CTPs were asked to participate in this study

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 6/2009 --